Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

6.800 +0.220 (+3.34%)
Streaming Delayed Price Updated: 1:53 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
News headline image
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS ↗
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Investor's Business Daily
Topics Government
News headline image
FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment ↗
FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory hurdles. 
Via Benzinga
News headline image
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care? ↗
AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Top 3 Health Care Stocks You'll Regret Missing In November ↗
 
Via Benzinga
News headline image
Uncovering Potential: Compass Pathways's Earnings Preview ↗
 
Via Benzinga
News headline image
Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript ↗
CMPS earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Nasdaq Down 500 Points; Uber Shares Dip After Q3 Results ↗
 
Via Benzinga
News headline image
As Psilocybin Trials Face Delays, Compass Pathways (CMPS) Cuts Workforce To Conserve Cash ↗
Compass Pathways delays key Phase 3 psilocybin trial readouts, triggering a 30% workforce reduction amid efforts to conserve cash and refocus. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Gains 1%; Meta Shares Fall Following Q3 Results ↗
 
Via Benzinga
News headline image
Estée Lauder, Robinhood, eBay And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates
From Compass Pathways plc
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024
From Compass Pathways plc
Via Business Wire
News headline image
Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes ↗
Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential. 
Via Benzinga
News headline image
Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder ↗
New study suggests psilocybin may help treat body dysmorphic disorder by rewiring brain connectivity and reducing obsessive thought patterns. 
Via Benzinga
News headline image
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
From Compass Pathfinder Limited
Via Business Wire
News headline image
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week ↗
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
Via Talk Markets
News headline image
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward? ↗
 
Via Benzinga
News headline image
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th ↗
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... 
Via Talk Markets
News headline image
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August ↗
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a... 
Via Talk Markets
News headline image
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down ↗
Lykos Therapeutics CEO Amy Emerson steps down following the FDA's rejection of the company's MDMA-based PTSD therapy. 
Via Benzinga
News headline image
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration ↗
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week ↗
Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past... 
Via Talk Markets
News headline image
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD ↗
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest... 
Via Talk Markets
News headline image
Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript ↗
CMPS earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves ↗
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.